Parkinson’s Disease: Professor David Devos Honored by the French National Academy of Medicine Press ReleasesBy December 18, 2025
InBrain Pharma to Present Long-Term Follow-Up Clinical Data from Its Phase I/II DIVE-I Trial in Parkinson’s Disease at the MDS 2025 Conference Press ReleasesBy September 22, 2025
France Parkinson takes a stake in InBrain Pharma, a company developing A-dopamine therapy for brain infusion Press ReleasesBy July 22, 2025
InBrain Pharma receives EMA Positive Scientific Advice supporting Phase 3 clinical development of A-dopamine for the treatment of advanced Parkinson’s disease Press ReleasesBy July 3rd, 2025
InBrain Pharma Secures €1.8 Million in Funding for the PERCEPAR Project under France 2030’s “First Factory” Initiative to Industrialize Anaerobic Dopamine Production for Parkinson’s Disease Press ReleasesBy May 12, 2025
A World Premiere in Parkinson’s Disease With significant clinical results published in the Nature Medicine Journal, InBrain Pharma is about to durably modify the advanced Parkinson’s disease management Press ReleasesBy January 27, 2025
InBrain Pharma to Present Positive Results from Its DIVE-I Phase I/II Clinical Trial for Parkinson’s Disease at the Congress of Parkinson’s Disease and Movement Disorders from September 27 to October 1 in Philadelphia Press ReleasesBy September 25, 2024
InBrain Pharma announces the publication of an article on the pharmacokinetic and pharmacodynamic limitations of L-DOPA in the management of Parkinson’s disease in the Journal of Parkinson’s Disease Press ReleasesBy September 1, 2024
European Inventor Award 2024 from the European Patent Office: Professors David Devos and Caroline Moreau, co-founders of InBrain Pharma, selected as finalists in the “Research” category for their therapeutic innovation in Parkinson’s disease Press ReleasesBy May 16, 2024
InBrain Pharma announces the completion of its DIVE-I phase I/II clinical trial in Parkinson’s disease. Press ReleasesBy May 2, 2024
